Cambridge Cognition Positive pipeline provides ‘Big wins for the business’ (Interview)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk to discuss winning increasing numbers of virtual clinical trials during COVID-19. Matthew talks us through the wins and explains what the company will be providing, the benefits of using virtual or part virtual assessments, using these kind of trials after COVID-19 and what we can expect to see from the company in the future.

Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company’s software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

You might also enjoy reading  Cambridge Cognition strong financial growth with a healthy pipeline of opportunities (LON:COG)
Find more news, interviews, share price & company profile here for:
Cambridge Cognition Holdings plc

Share this interview

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp
Virtual Trials Covid 19
Cambridge Cognition Positive pipeline provides ‘Big wins for the business’ (Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions